Occupational Activity
FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts
United States Food and Drug Administration, PDUFA, Impact food supplement, Approved, Agencies, questions
Regeneron crumples under the weight of missed Eylea expectations
Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Merck & Co. breaks ground on $1B future US home of Keytruda
United States, Keytruda, Home environment, Merck, Wilmington, Biological Factors
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies
Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher
Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge
Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration
Lotte Bio launches ADC services; Ypsomed to focus on self-injection business
Antibody-Drug Conjugates, Lotte, Ypsomed, Services, Biological Factors, Manufacture, self-injection business